Back to top

Image: Bigstock

Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia

Read MoreHide Full Article

Key Takeaways

  • Ionis wins EU approval for Tryngolza to treat adults with severe hypertriglyceridemia.
  • Tryngolza becomes the first RNA-targeted therapy approved in the EU for this patient population.
  • The EU approval was supported by positive data from the phase III CORE and CORE2 studies.

Ionis (IONS - Free Report) announced that the European Commission has approved the expanded use of Tryngolza (olezarsen) for the treatment of adults with severe hypertriglyceridemia (sHTG) who have fasting triglyceride levels of at least 880 mg/dL.The drug will be used along with diet and other lipid-lowering therapies.

The approval was expected as the Committee for Medicinal Products for Human Use of the European Medicines Agency had issued a positive opinion in October 2026 recommending Tryngolza's approval for the said indication.

With the latest approval, Tryngolza becomes the first RNA-targeted therapy approved in the European Union (EU) for this patient population. In 2025, the drug was approved in this region for familial chylomicronemia syndrome (FCS) and the latest decision expands its use to a broader patient population. In June 2026, the FDA also approved Tryngolza for treating adults with sHTG in the United States.

Year to date, IONS’ shares have plunged 65.9% compared with the industry’s 1.8% fall.

Zacks Investment Research
Image Source: Zacks Investment Research

sHTG is a condition marked by triglyceride levels of at least 500 mg/dL. Patients with very high triglyceride levels (at least 880 mg/dL) face an increased risk of acute pancreatitis, a life-threatening condition that can cause severe abdominal pain, prolonged hospitalization and permanent organ damage.

The EU approval of Tryngolza for sHTG was based on positive results from the phase III CORE and CORE2 studies. Both studies met their primary endpoints, showing significant reductions in fasting triglyceride levels compared with placebo. The drug also reduced acute pancreatitis events and demonstrated a favorable safety and tolerability profile.

Ionis markets Tryngolza in the United States, while its partner Sobi holds exclusive commercialization rights outside the United States, Canada and China. The latest EU approval expands the drug's commercial opportunities in Europe.

IONS' Tryngolza Sales Performance in 2026

Tryngolza, Ionis' first wholly owned commercial product, was initially approved by the FDA for FCS in December 2024. The drug’s recent label expansion to include sHTG in the United States offers a significantly larger market opportunity than its initial FCS indication. However, its commercial performance has been weaker than expected in 2026.

Tryngolza generated net product sales of $41 million in the first nine months of 2026, down 28.5% year over year. The drug recorded sales of approximately $9 million in the third quarter of 2026,missing the Zacks Consensus Estimate of $23.1 million. Management attributed the underperformance to a more gradual-than-anticipated launch ramp, as physicians take time to adopt the new treatment and reimbursement coverage gradually expands. Reflecting these headwinds, Ionis slashed its full-year 2026 Tryngolza sales guidance from its earlier projection of $100-$110 million to approximately $50 million.

Ionis’ Zacks Rank & Stocks to Consider

IONS currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) ,currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have surged 67.6% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 32.8% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.

Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 75.4% year to date.

Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.

Published in